US 11,857,548 B2
Methods of treatment
Sundar Srinivasan, Corona Del Mar, CA (US); and Christina Chow Wallen, Seattle, WA (US)
Assigned to BOW RIVER LLC, Corona Del Mar, CA (US)
Filed by BOW RIVER LLC, Corona Del Mar, CA (US)
Filed on Mar. 8, 2023, as Appl. No. 18/118,911.
Application 17/099,298 is a division of application No. 16/191,351, filed on Nov. 14, 2018, granted, now 10,835,529, issued on Nov. 17, 2020.
Application 18/118,911 is a continuation of application No. 17/949,889, filed on Sep. 21, 2022.
Application 17/949,889 is a continuation of application No. 17/700,947, filed on Mar. 22, 2022, granted, now 11,491,152, issued on Nov. 8, 2022.
Application 17/700,947 is a continuation of application No. 17/469,628, filed on Sep. 8, 2021, granted, now 11,351,160, issued on Jun. 7, 2022.
Application 17/469,628 is a continuation in part of application No. 17/407,440, filed on Aug. 20, 2021.
Application 17/469,628 is a continuation of application No. 17/244,065, filed on Apr. 29, 2021, granted, now 11,154,545, issued on Oct. 26, 2021.
Application 17/244,065 is a continuation of application No. 17/150,467, filed on Jan. 15, 2021, granted, now 11,052,077, issued on Jul. 6, 2021.
Application 17/407,440 is a continuation of application No. 17/099,298, filed on Nov. 16, 2020, granted, now 11,123,346, issued on Sep. 21, 2021.
Application 17/150,467 is a continuation of application No. 17/082,902, filed on Oct. 28, 2020, granted, now 11,730,724.
Application 17/082,902 is a continuation of application No. 16/408,931, filed on May 10, 2019, granted, now 10,857,144, issued on Dec. 8, 2020.
Application 16/191,351 is a continuation in part of application No. 15/596,585, filed on May 16, 2017, granted, now 10,376,507, issued on Aug. 13, 2019.
Application 16/408,931 is a continuation in part of application No. 15/596,585, filed on May 16, 2017, granted, now 10,376,507, issued on Aug. 13, 2019.
Prior Publication US 2023/0241058 A1, Aug. 3, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/496 (2006.01); A61P 35/00 (2006.01); A61P 35/02 (2006.01); A61P 25/18 (2006.01); A61P 25/16 (2006.01); A61P 35/04 (2006.01); A61K 9/00 (2006.01); A61K 9/08 (2006.01); A61K 9/10 (2006.01); A61K 9/20 (2006.01); A61K 9/48 (2006.01); A61K 31/00 (2006.01); A61K 31/397 (2006.01); A61K 31/407 (2006.01); A61K 31/4468 (2006.01); A61K 31/454 (2006.01); A61K 31/4745 (2006.01); A61K 31/497 (2006.01); A61K 31/498 (2006.01); A61K 31/4995 (2006.01); A61K 31/506 (2006.01); A61K 31/519 (2006.01); A61K 31/5383 (2006.01); A61K 31/5395 (2006.01); A61K 31/502 (2006.01)
CPC A61K 31/496 (2013.01) [A61K 9/0019 (2013.01); A61K 9/0053 (2013.01); A61K 9/0056 (2013.01); A61K 9/0078 (2013.01); A61K 9/0095 (2013.01); A61K 9/08 (2013.01); A61K 9/10 (2013.01); A61K 9/2004 (2013.01); A61K 9/4841 (2013.01); A61K 31/00 (2013.01); A61K 31/397 (2013.01); A61K 31/407 (2013.01); A61K 31/4468 (2013.01); A61K 31/454 (2013.01); A61K 31/4745 (2013.01); A61K 31/497 (2013.01); A61K 31/498 (2013.01); A61K 31/4995 (2013.01); A61K 31/502 (2013.01); A61K 31/506 (2013.01); A61K 31/519 (2013.01); A61K 31/5383 (2013.01); A61K 31/5395 (2013.01); A61P 25/16 (2018.01); A61P 25/18 (2018.01); A61P 35/02 (2018.01); A61P 35/04 (2018.01)] 24 Claims
 
1. A method of treating mantle cell lymphoma (MCL), Waldenström's macroglobulinemia (WM), marginal zone lymphoma (MZL), chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), or chronic graft versus host disease (cGVHD) in a patient in need thereof with an anti-neoplastic drug, wherein the patient is treated with a strong CYP3A4 inhibitor, comprising:
a. discontinuing the strong CYP3A4 inhibitor treatment;
b. delaying administering, for at least about 3 days after discontinuing the strong CYP3A4 inhibitor treatment, a dose of the anti-neoplastic drug that the patient would have received based on the patient's age and condition if the patient had not been treated with the strong CYP3A4 inhibitor; and then
c. administering the dose of the anti-neoplastic drug that the patient would have received based on the patient's age and condition if the patient had not been treated with the strong CYP3A4 inhibitor;
wherein the strong CYP3A4 inhibitor is posaconazole.